GLP-1受体激活剂作为WFS1频谱障碍中的有希望的疾病修饰剂
Eleonora Panfili1, Giulio Frontino2, Maria Teresa Pallotta1
1Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Frontiers in clinical diabetes and healthcare
|June 19, 2023
概括
WFS1谱系障碍 (WFS1-SD) 是一种罕见的遗传神经退行性疾病. GLP-1受体激动剂在减少ER压力和可能延迟疾病进展方面表现有前途.
科学领域:
- 神经遗传学 神经遗传学
- 内分泌学 在内分泌学.
- 细胞生物学 细胞生物学
背景情况:
- WFS1谱系障碍 (WFS1-SD) 是一种罕见的单一性神经退行性疾病.
- 主要症状包括儿童发病的糖尿病,视力缩,聋和神经缺陷.
- 这种疾病是由WFS1基因突变引起的,导致ER压力和细胞死亡.
研究的目的:
- 总结GLP-1受体激动剂的特征.
- 审查关于WFS1-SD.中的GLP-1受体激动剂的临床前和临床数据.
- 评估GLP-1受体激动剂用于管理WFS1-SD的可行性.
主要方法:
- 审查关于WFS1-SD. 的现有文献.
- 涉及GLP-1受体激动剂的临床前研究分析.
- 对WFS1-SD.中的GLP-1受体激动剂的临床试验数据的检查.
主要成果:
- GLP-1受体激动剂在减少ER压力方面表现出有效性,在体外和体内.
- 新出现的数据表明,延缓WFS1-SD进展可能有好处.
- 目前对于WFS1-SD.没有确定的治愈或治疗方法.
结论:
- GLP-1受体激动剂代表了WFS1-SD的潜在治疗策略.
- 需要进一步的研究和临床试验来证实疗效.
- 管理ER压力是WFS1-SD治疗的关键目标.
相关概念视频
Glucagon-like Receptor Agonists
369
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
369
G Protein-coupled Receptors
12.3K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
12.3K
Lysosomal Hydrolases
3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
218
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
218
Oral Hypoglycemic Agents: Glinides
190
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
190
Pleiotropy
40.7K
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
40.7K


